Accession Number:

AD1107364

Title:

TCR-Engineered T Cell Immunotherapy for Epithelial Ovarian Cancer Enhanced by TGFbeta Blockade and Epigenetic Modulation

Descriptive Note:

Technical Report,15 Jul 2018,14 Jul 2019

Corporate Author:

Roswell Park Comprehensive Cancer Center BUFFALO United States

Personal Author(s):

Report Date:

2019-08-01

Pagination or Media Count:

5.0

Abstract:

This is a project to test the hypothesis that the combination of epigenetic modification Decitabine and adoptive cell therapy ACT of NY- ESO-1 TCR dnTGFBetaRII engineered T cells will be safe and show improved clinical responses in women who have recurrentpersistent platinum-resistant ovarian cancers. We had successfully reached the milestones for the first year We injected the highest dose of T cell 10e9 transgenic T cells in the last cohort of our Phase I clinical trial with NY-ESO-1 TCRdnTGFBetaRII engineered T cells for solid- tumors including Ovarian Ca. FDA approval IND 17410, clinicaltrials.gov reg. NCT02650986. And we successfully got approval from IRB and FDA to add Decitabine to the clinical trial as proposed.

Subject Categories:

  • Medicine and Medical Research

Distribution Statement:

APPROVED FOR PUBLIC RELEASE